Full Press Release Details
Sagimet Biosciences to Host Virtual KOL Event, 'A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne' on June 16, 2025.
SGMT
Sagimet Biosciences to Host Virtual KOL Event, 'A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne' on June 16, 2025
Key Takeaway: Sagimet Biosciences to Host Virtual KOL Event, 'A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne' on June 16, 2025
Price reaction · baseline $5.56 (2025-06-06 close) · clean, no other SGMT news in the window
day 0 close · peak
-4.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease